Achaogen

South San Francisco, CA · Biotech · Defunct

Plazomicin, an aminoglycoside antibiotic molecule for treating carbapenem-resistant bacterial infections

Claim this profile

Follows are private to you and power your alerts

Updated Oct 23, 2026 · achaogen.com

Sector: Biotech
Headquarters: South San Francisco, CA
Latest Form D: $10M, May 2017
Total capital: $304M

Federal grants: None on recordNo awards found in SBIR/STTR, NIH, NSF or DoD records.
Private capital raised: $89.7M; 4 Form D · last May 2017; 113 months since last filing
Federal contracts: $214M; 7 awards · Defense, Health and Human S; Rank in Biotech#4 of 4373
Granted patents: 9; 31 pending · first 2014; Rank in peer group#179 of 1449

Capital timeline

Latest events

Sep 2017Federal contractHealth and Human S · Igf::ot::igf Achaogen$6M
May 2017Private capital raisedForm D · SEC · 4th filing$10M
Jun 2016Private capital raisedForm D · SEC · 3rd filing$25.4M
Apr 2015Federal contractHealth and Human S · Igf::ot::igf "novel Lpxc Inhibitors For The Treatment Of Category A, B, And C Bacterial Infections"$4.7M
Mar 2013Private capital raisedForm D · SEC · 2nd filing$18.9M
Aug 2010Federal contractHealth and Human S · TAS::75 0140::TAS$124M
Jul 2010Federal contractDefense · Development Of ACHN-490 For The Treatment Of Lung Infection Caused By Mdr Acinetobacter Baumannii And Other Pathogens R&d Effort.$1.9M
Apr 2010Private capital raisedForm D · SEC · 1st filing$35.4M

Show 3 earlier federal awards

Sep 2008Federal contractHealth and Human S · New Contract Award Under Rfp: Baa NIH-NIAID-DMID-08-20$21.1M
Jun 2007Federal contractDefense · Base Period$40.6M
Oct 2006Federal contractDefense · Preclinical Development Of Novel Therapeutics That Attenuate Virulence Of, And Inhibit Resistance In, Class A Bacterial Pathogens$15.1M

Node area is scaled to amount. Form D reports securities sold, which can differ from an announced round; filings are numbered in the order they were made.

Federal first

42months

from Achaogen’s first federal award to its first private round.

First federal award · Oct 2006: Defense · $15.1M
First Form D · Apr 2010: $35.4M · 1st Form D
Awards before first raise: 3 awards

An association in public records, not a cause or a prediction.

Standing among 1449 peers

Line = median

Biotech · Molecule

Granted patents#179 · top 12%

Cumulative measures favor older companies. Rankings describe position today, not outcome. Below the median, ranks show as a band rather than a number.

Founders and team

From SEC Form D filings

Alan B. ColowickDirectorNamed in SEC Form D filings
Becki J. FiliceExecutive OfficerNamed in SEC Form D filings
Blake R. WiseExecutive OfficerNamed in SEC Form D filings
Bryan E. RobertsDirectorNamed in SEC Form D filings
Camille D. SamuelsDirectorNamed in SEC Form D filings
Christine J. WelchExecutive OfficerNamed in SEC Form D filings

Show all 29 people

Christopher J. WalshDirectorNamed in SEC Form D filings
Dennis J. HomExecutive OfficerNamed in SEC Form D filings
Gary W. LoebExecutive OfficerNamed in SEC Form D filings
Gregory W. SteaDirectorNamed in SEC Form D filings
Halley E. GilbertDirectorNamed in SEC Form D filings
Heinz E. MoserExecutive OfficerNamed in SEC Form D filings
Ian R. FriedlandExecutive OfficerNamed in SEC Form D filings
J. Kevin JudiceExecutive Officer, DirectorNamed in SEC Form D filings
John J. DoyleDirectorNamed in SEC Form D filings
John F. HollwayExecutive OfficerNamed in SEC Form D filings
John W. SmitherDirectorNamed in SEC Form D filings
Jon B. BrussExecutive OfficerNamed in SEC Form D filings
Kenneth J. HillanExecutive Officer, DirectorNamed in SEC Form D filings
Kenneth E. NussbacherDirectorNamed in SEC Form D filings
Kent E. LiegingerDirectorNamed in SEC Form D filings
Lee C. SwemExecutive OfficerNamed in SEC Form D filings
Michael C. FischbachDirectorNamed in SEC Form D filings
Robert D. MoreDirectorNamed in SEC Form D filings
Scott J. RocklageDirectorNamed in SEC Form D filings
Thomas D. KingDirectorNamed in SEC Form D filings
Tobin C. SchilkeExecutive OfficerNamed in SEC Form D filings
Troy J. CoxDirectorNamed in SEC Form D filings
Zeryn R. SarpangalExecutive OfficerNamed in SEC Form D filings

What it has protected

USPTO · 9 granted of 40

Apr 21, 2020GrantedCombination Products For The Treatment Of Bacterial Infections And Methods Of Producing Or Dosing Of SameUSPTOUS 10,624,899
Dec 12, 2019PendingTreatment Of Klebsiella Pneumoniae Infections With Antibacterial Aminoglycoside CompoundsUSPTOApplication 16240370
Nov 26, 2019GrantedAntibacterial Aminoglycoside AnalogsUSPTOUS RE47,741

Show all 40 patent records

Combination Products For The Treatment Of Bacterial Infections And Methods Of Producing Or Dosing Of SameApr 21, 2020 · US 10,624,899Granted
Treatment Of Klebsiella Pneumoniae Infections With Antibacterial Aminoglycoside CompoundsDec 12, 2019 · Application 16240370Pending
Antibacterial Aminoglycoside AnalogsNov 26, 2019 · US RE47,741Granted
Screening Methods For Identifying Antibodies That Bind Cell Surface EpitopesJan 31, 2019 · Application 16071898Pending
Antibacterial AgentsDec 28, 2017 · Application 15615276Pending
Antibacterial AgentsJul 11, 2017 · US 9,701,622Granted
Antibacterial Aminoglycoside AnalogsJun 27, 2017 · US 9,688,711Granted
Antibacterial AgentsApr 11, 2017 · US 9,617,256Granted
Antibacterial AgentsMar 30, 2017 · Application 15376073Pending
Antibacterial AgentsAug 2, 2016 · US 9,403,758Granted
Antibacterial Aminoglycoside AnalogsFeb 23, 2016 · US 9,266,919Granted
Antibacterial AgentsJun 25, 2015 · Application 14536286Pending
Antibacterial Aminoglycoside AnalogsSep 2, 2014 · US 8,822,424Granted
Antibacterial Aminoglycoside AnalogsFeb 18, 2014 · US 8,653,041Granted
Screening Methods For Identifying Antibodies That Bind Cell Surface EpitopesApplication PCTUS2017015515Pending
Plazomicin Antibodies And Methods Of UseApplication 62370580Pending
6-PHENYLPYRIDO[2,3-D]PYRIMIDINE Compounds As Antibacterial AgentsApplication 62368331Pending
Combination Products for the Treatment of Bacterial Infections and Methods of Producing or Dosing of SameApplication 62362293Pending
Antibacterial AgentsApplication 62353910Pending
Aminoglycoside Dosing RegimensApplication PCTUS2010035006Pending
Screening Methods For Identifying Antibodies That Bind Cell Surface EpitopesApplication 62288729Pending
Antibacterial AgentsApplication PCTUS2014024304Pending
Antibacterial AgentsApplication PCTUS2013040571Pending
Antibacterial AgentsApplication PCTUS2013040350Pending
Antibacterial AgentsApplication 61777540Pending
Antibacterial AgentsApplication 61777547Pending
Polymorphs Of N-((S)-3-AMINO-1-(HYDROXYAMINO)-3-METHYL-1-OXOBUTAN-2-YL)-4-(((1R,2R)-2-(HYDROXYMETHYL)CYCLOPROPYL)BUTA-1,3-DIYNYL)BENZAMIDEApplication PCTUS2012054718Pending
Antibacterial Amiinoglycoside AnalogsApplication PCTUS2011060513Pending
Antibacterial Aminoglycoside AnalogsApplication PCTUS2010052043Pending
Antibacterial Aminoglycoside AnalogsApplication PCTUS2010052040Pending
Antibacterial Aminoglycoside AnalogsApplication PCTUS2010052045Pending
Antibacterial Aminoglycoside AnalogsApplication PCTUS2010052109Pending
Antibacterial Aminoglycoside AnalogsApplication PCTUS2010052044Pending
Combination Therapies Using Antibacterial Aminoglycoside CompoundsApplication PCTUS2010038138Pending
Antibacterial Aminoglycoside AnalogsApplication PCTUS2010034893Pending
Antibacterial Aminoglycoside AnalogsApplication PCTUS2010034888Pending
Treatment Of Urinary Tract Infections With Antibacterial Aminoglycoside CompoundsApplication PCTUS2010034909Pending
Treatment Of Klebsiella Pneumoniae Infections With Antibacterial Aminoglycoside CompoundsApplication PCTUS2010034898Pending
Antibacterial Aminoglycoside AnalogsApplication PCTUS2010034884Pending
Antibacterial Aminoglycoside AnalogsApplication PCTUS2010034896Pending

MAPP BIOPHARMACEUTICAL, INC.Similar federal contract value in Biotech · $586M in contracts
INTEGRATED LABORATORY SYSTEMS, LLCSimilar federal contract value in Biotech · $271M in contracts
VENATORX PHARMACEUTICALS INCSimilar federal contract value in Biotech · $270M in contracts
Ginkgo BioworksSimilar federal contract value in Biotech · $191M in contracts
Cellerant Therapeutics, Inc.Similar federal contract value in Biotech · $185M in contracts
Sarepta TherapeuticsSimilar federal contract value in Biotech · $169M in contracts

Regulatory activity · Biotech

Sector-level, not company-level

07 Jul 2026New Animal Drugs; Approval of New Animal Drug Applications; Withdrawal of Approval of New Animal Drug Application; Change of SponsorFood and Drug Administration
30 Jun 2026Medical Devices; General and Plastic Surgery Devices; Classification of the Skin Patch for Treatment of HyperhidrosisFood and Drug Administration
30 Jun 2026Medical Devices; Anesthesiology Devices; Classification of the Monitor for Opioid Induced Impairment of OxygenationFood and Drug Administration
29 Jun 2026Medical Devices; Orthopedic Devices; Classification of the Medial Knee Implanted Shock AbsorberFood and Drug Administration
26 Jun 2026Medical Devices; Neurological Devices; Classification of the External Lower Extremity Nerve Stimulator for Restless Legs SyndromeFood and Drug Administration
26 Jun 2026Medical Devices; General Hospital and Personal Use Devices; Classification of the Infant Supine Sleep SystemFood and Drug Administration

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.

Sources

Federal grants from SBIR/STTR, NIH, NSF and DoD records. Federal contracts from USAspending.gov. Private capital from SEC Form D. Patents from USPTO. Publications from OpenAlex. Regulatory activity from the Federal Register. Press matched on company name.

How to read this page

Figures show associations in public records, not causes or predictions. Nothing here is investment advice. An em-dash means no record was found under this company's name, not that none exists.

Data freshness

SEC Form D filings through Oct 23, 2026. SBIR and STTR awards through Oct 21, 2026.